# Adjunctive Effects of Psilocybin and a Formulation of Buprenorphine

> **NCT04161066** · PHASE1 · RECRUITING · sponsor: **University of Wisconsin, Madison** · enrollment: 10 (estimated)

## Conditions studied

- Opioid Use Disorder

## Interventions

- **DRUG:** Psilocybin with facilitated counseling

## Key facts

- **NCT ID:** NCT04161066
- **Lead sponsor:** University of Wisconsin, Madison
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2021-01-13
- **Primary completion:** 2026-06
- **Final completion:** 2026-07
- **Target enrollment:** 10 (ESTIMATED)
- **Last updated:** 2025-10-15

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04161066

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04161066, "Adjunctive Effects of Psilocybin and a Formulation of Buprenorphine". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT04161066. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*